

An informed perspective on the quest for immortality

May 11 2022



Credit: CC0 Public Domain

A new research perspective published in *Oncoscience* by Mikhail Blagosklonny, M.D., Ph.D., looks at the possibility of immediate life extension using rapamycin.

"Here I discuss how combining rapamycin with other modalities may let us live long enough to benefit from future discoveries in [cellular reprogramming](#) and what needs to be done at Altos Labs to make this happen," the perspective states.

Altos Labs—a new anti-aging [biotechnology company](#) funded by multiple billionaire investors, including Jeff Bezos and Yuri Milner—has reported a focus on reprogramming [cells](#) in order to reverse the trajectory of diseases, and thus, reverse aging.

In his research perspective, Dr. Blagosklonny writes that potential life-extension with rapamycin may allow us to win time while awaiting future discoveries that will reverse aging.

"Rapamycin treatment is rapidly becoming a mainstream anti-aging intervention," he writes.

However, Dr. Blagosklonny also writes that rapamycin alone is unlikely to extend lifespan sufficiently to benefit from Altos Labs' future discoveries in our lifetime.

"If Altos Labs would allocate a small percentage of its funding to develop rapamycin based drug combinations, then additional decades of life extension may be available 3–5 years from now," he writes. "The number of potential combinations with rapamycin is enormous."

More information: Mikhail V. Blagosklonny, Altos Labs and the quest for immortality: but can we live longer right now?, *Oncoscience* (2022). [DOI: 10.18632/oncoscience.552](https://doi.org/10.18632/oncoscience.552)

Citation: An informed perspective on the quest for immortality (2022, May 11) retrieved 11 July 2023 from <https://medicalxpress.com/news/2022-05-perspective-quest-immortality.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.